Halozyme Therapeutics stock is trading -17.97% below its average target price of $64.12 after marking a 2.8% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an average rating of buy and target prices ranging from $52.0 to $75.0 per share.
The stock has an above average percentage of its shares sold short at 9.3%, and a short ratio of 4.31. Since 1.06% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 100.8% of Halozyme Therapeutics's shares being owned by this investor type.
Institutions Invested in Halozyme Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Blackrock Inc. | 14% | 17,430,019 | $916,818,972 |
| 2024-09-30 | Vanguard Group Inc | 10% | 12,895,096 | $678,282,029 |
| 2024-09-30 | State Street Corporation | 5% | 6,633,688 | $348,931,978 |
| 2024-09-30 | Snyder Capital Management, LP | 3% | 4,063,367 | $213,733,097 |
| 2024-09-30 | Alliancebernstein L.P. | 3% | 3,408,341 | $179,278,731 |
| 2024-09-30 | Artisan Partners Limited Partnership | 2% | 3,133,412 | $164,817,466 |
| 2024-09-30 | Geode Capital Management, LLC | 2% | 3,060,131 | $160,962,885 |
| 2024-09-30 | Macquarie Group Limited | 2% | 3,010,825 | $158,369,390 |
| 2024-09-30 | JP Morgan Chase & Company | 2% | 2,864,857 | $150,691,473 |
| 2024-09-30 | Congress Asset Management Co | 2% | 2,433,579 | $128,006,251 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Halozyme Therapeutics.
